Abstract
In patients with interstitial lung disease, exertional hypoxaemia has quality of life and prognostic implications. A simple “DeOX” score predictive of exertional oxygen desaturation (SpO2 ≤88% on 6MWT) is proposed, using SpO2 at rest and DLCO. http://bit.ly/36ytigE
To the Editor:
In patients with fibrotic interstitial lung disease (ILD), hypoxaemia on exertion is frequent, and contributes to exercise intolerance, exertional dyspnoea and reduced quality of life [1–3]. Clinically significant exertional hypoxaemia is typically defined as a drop in transcutaneous arterial oxygen saturation (SpO2) to ≤88% on a 6-min walk test (6MWT) [4], and is associated with reduced survival in ILD patients [5].
In the AmbOx trial, ambulatory oxygen was associated with improved health-related quality of life in ILD patients with isolated exertional hypoxaemia [6]. Although exertional desaturation has been correlated with gas transfer measurements [7, 8], few data are available on the predictors of a drop of SpO2 to ≤88% in ILD, and no physiological parameter thresholds have been identified to help select ILD patients who would most benefit from performing a 6MWT.
We analysed predictors of oxygen desaturation (SpO2 ≤88%) on 6MWT in ILD patients without severe resting hypoxia (SpO2 at rest ≥92%) in a derivation cohort (n=146; patients screened at the Royal Brompton Hospital (RBH; London, UK) for the AmbOx study between September 2014 and July 2016) [6] and a validation cohort (n=154; consecutive ILD referrals to RBH seen between August 2016 and May 2018). Approval for this study was obtained from the RBH institutional ethics committee. Patients requiring oxygen at rest and/or with clinical signs of right heart failure and/or symptomatic ischaemic heart disease were excluded. Lung function tests including forced vital capacity (FVC), forced expiratory volume (FEV1) and diffusing capacity of the lung for carbon monoxide (DLCO) were performed in all patients within 6 months of the 6MWT. The composite physiological index (CPI) was used as a functional index of lung fibrosis severity [9]. The 6MWT was performed as described previously [10]. Categorical variables were compared using the Chi-squared test or the Fisher exact test and continuous variables with t-test or nonparametric Mann–Whitney test, as appropriate. Univariable logistic regression analysis was used to identify variables predictive of 6MWT oxygen desaturation. Any factors potentially associated on univariable analysis with SpO2 ≤88% on 6MWT (p<0.10) were added to the multivariable model. If two variables were highly correlated (r coefficient >|±0.30|), the one with the largest variance was excluded from the multivariable analysis [11]. Finally, a backward stepwise selection (p-in <0.05, p-out >0.10) was used to determine the factors independently associated with SpO2 ≤88% on 6MWT. Receiver operating characteristic analyses were performed on significant variables derived from the final logistic regression models, and optimal cut-off points for each variable were identified by using Youden's index. The Hosmer–Lemeshow goodness-of-fit test was performed to assess the overall fit of the final models. All statistical analyses were performed using IBM SPSS (version 25.0; IBM, Armonk, NY, USA). A p-value of <0.05 was considered statistically significant.
A total of 300 ILD patients (derivation cohort n=146, validation cohort n=154) were included in the analysis. Age, sex and smoking history did not differ significantly between the two cohorts (derivation cohort: age 66.5±10.4 years, male 65%, ever-smokers 55.5%; validation cohort: age 65.2±10.7 years, male 61%, ever-smokers 55.8%). Overall, 112 (37.3%) patients had a multidisciplinary team diagnosis of IPF, 65 (21.6%) chronic hypersensitivity pneumonitis, 35 (11.7%) connective tissue disease-associated ILD, 14 (4.7%) nonspecific interstitial pneumonia, eight (2.7%) sarcoidosis and 66 (22%) other ILDs. Patients from the validation cohort had less-severe disease (mean±sd CPI 44.4±13 versus 52.9±10.6, p=0.0001) and were less likely to desaturate on 6MWT (26% versus 63%, p<0.001). For the 297 patients with available computed tomography scans (derivation cohort n=144, validation cohort n=153), emphysema was scored as absent (emphysema score=0), limited (visible in the upper areas of the lung but not reaching the carina; emphysema score=1) and extensive (reaching the carina or further caudally; emphysema score=2). Limited emphysema was present in 23 (16%) and 12 (7.8%) patients in the derivation and validation cohorts, respectively, while extensive emphysema was present in five (3.5%) and six (3.9%) patients, respectively.
On univariable analysis, variables associated with desaturation on 6MWT in the derivation cohort included SpO2 at rest (OR 0.57, 95% CI 0.45–0.73), DLCO % (OR 0.94, 95% CI 0.91–0.97), FVC % (OR 0.97, 95% CI 0.96–0.99), FEV1 % (OR 0.98, 95% CI 0.96–0.99) and CPI (OR 1.06, 95% CI 1.02–1.09), and were confirmed in the validation cohort (data not shown), while diagnosis of idiopathic pulmonary fibrosis (IPF), age, sex, body mass index and smoking history were not associated in either cohort. On multivariable analysis, only DLCO and SpO2 remained independently predictive of oxygen desaturation on 6MWT ≤88% in each cohort, with adjustment for age, sex, smoking history and either SpO2 or DLCO as appropriate (adjusted (a) odds ratios for DLCO in derivation cohort aOR 0.94, 95% CI 0.90–0.98, p=0.002 and validation cohort aOR 0.91, 95% CI 0.87–0.95, p<0.0001; for resting SpO2 in derivation cohort aOR 0.56, 95% CI 0.43–0.73, p<0.0001 and validation cohort aOR 0.57, 95% CI 0.43–0.74, p<0.0001). The optimal predictive thresholds for DLCO (≤40%) and SpO2 (≤95%) were identified in the derivation cohort and confirmed in the validation cohort. The two variables were then integrated into a predictive “DeOX” score (0–2; 0=SpO2 >95% and DLCO >40%; 1=SpO2 ≤95% or DLCO ≤40%; 2=DLCO ≤40% and SpO2 ≤95%). The presence of one or both variables progressively increases the risk of desaturation in both cohorts, separately and in combination (figure 1). Considering both cohorts together, our data show that with a DeOX score of 1, the odds ratio for 6MWT desaturation was 8.1 (95% CI 4.14–15.88) with a likelihood ratio of 1.5 (95% CI 1.1–1.4), and increased markedly with a score of 2 (OR 24.8, 95% CI 11.78–57.04) with a likelihood ratio of 4.4 (95% CI 2.6–3.5). The strength of this association did not change on adjusting for the presence of the emphysema score in the multivariable analysis in each cohort separately, or in both combined (for both cohorts OR 8.7, 95% CI 4.4–17.3 for a DeOX score of 1, and OR 25.7, 95% CI 11.1–59.1 for a score of 2). Of note, 78.5% of patients with a DeOX score of 2 desaturated on a 6MWT, highlighting the cohort of ILD patients for whom more efforts should be made to ensure that oxygen desaturation on exercise is promptly tested.
Odds ratio for desaturation (transcutaneous arterial oxygen saturation (SpO2) ≤88%) on 6-min walk test (6MWT), according to presence of neither (score=0), one (score=1) or both (score=2) thresholds (diffusing capacity of the lung for carbon monoxide (DLCO) ≤40%; SpO2≤95%). All patients: OR 8.1 (95% CI 4.14–15.88) for score=1, and 24.8 (95% CI 11.78–57.04) for score=2. Derivation cohort: OR 4.5 (95% CI 1.77–11.53) for score=1, and 23.9 (95% CI 6.37–89.86) for score=2. Validation cohort: OR 13.4 (95% CI 4.19–42.87) for score=1, and 27.3 (95% CI 7.31–101.57) for score=2. All odds ratios are adjusted for anthropometric characteristics. Hosmer–Lemeshow goodness-of-fit tests p=0.995, p=0.92 and p=0.56 for multivariate adjusted models in all patients, derivation and validation cohorts, respectively.
To our knowledge, this is the largest study correlating physiological variables with the likelihood of oxygen desaturation on 6MWT in fibrotic ILD patients. Our novel predictive score combines DLCO and SpO2 at rest; two non-invasive variables readily obtainable in a respiratory service. The limited time and staff available in busy outpatient services mean that the 6MWT is not consistently performed on routine follow-up, and the identification of exertional hypoxia may be missed. The finding that DLCO and SpO2 are independent determinants of oxygen desaturation on exercise suggests that two separate phenomena are being captured. While in DLCO we have our best measure of morphological disease severity, a lower SpO2 for a given DLCO is likely to be linked to an important pulmonary vascular component [12, 13].
Our study has a number of limitations, including its retrospective nature. However, the predictive ability of the identified thresholds was observed in two independent cohorts, improving the confidence in our findings. The two cohorts differed in severity, with a significantly higher proportion of patients desaturating on 6MWT in the derivation compared to the validation cohort. The derivation cohort comprised patients screened for the AmbOx trial. Clinicians referring patients for a trial of supplemental oxygen will have been more likely to select those with more extensive ILD and/or reporting significant breathlessness on exertion. There was no selection bias for the validation cohort, where all consecutive patients not requiring oxygen at rest and meeting our exclusion criteria were included. Of interest, the score worked best in this less severe “unselected” validation cohort, more likely to be representative of the ILD population attending respiratory services. All patients were seen in the same centre with a centralised lung function lab. As DLCO measurements can be subject to interlaboratory variation, the findings should be confirmed in different centres, in order to confirm the robustness of the score across different lung function facilities. Finally, as the 6MWT was performed at sea level, the validity of the score should be tested at different altitudes.
In conclusion, our data suggest that resting SpO2 and DLCO percentage are independently correlated with significant desaturation on a 6MWT. We propose a novel simple scoring system to predict the risk of oxygen desaturation during 6MWT in patients with ILD, using a combination of two easily obtainable non-invasive physiological variables. We suggest that if confirmed by different centres, this score could be useful in clinical practice to screen for ILD patients likely to benefit from a formal 6MWT.
Shareable PDF
Supplementary Material
This one-page PDF can be shared freely online.
Shareable PDF ERJ-01681-2019.Shareable
Footnotes
Conflict of interest: V. Alfieri has nothing to disclose.
Conflict of interest: E. Crisafulli has nothing to disclose.
Conflict of interest: D. Visca has nothing to disclose.
Conflict of interest: W.H. Chong has nothing to disclose.
Conflict of interest: C. Stock has nothing to disclose.
Conflict of interest: L. Mori has nothing to disclose.
Conflict of interest: A. de Lauretis has nothing to disclose.
Conflict of interest: V. Tsipouri has nothing to disclose.
Conflict of interest: F. Chua reports lecture fees and advisory board fees from Boehringer Ingelheim and from Roche, outside the submitted work.
Conflict of interest: V. Kouranos has nothing to disclose.
Conflict of interest: M. Kokosi has nothing to disclose.
Conflict of interest: C. Hogben has nothing to disclose.
Conflict of interest: P.L. Molyneaux has, via his institution, received industry-academic funding from Roche, Boehringer Ingelheim and Galapagos and has received speaker fees from Roche.
Conflict of interest: P.M. George reports grants, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Roche, personal fees from Teva, outside the submitted work.
Conflict of interest: T.M. Maher has, via his institution, received industry-academic funding from GlaxoSmithKline R&D and UCB and has received consultancy or speaker fees from Apellis, AstraZeneca, Bayer, Blade Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Galapagos, GlaxoSmithKline R&D, Indalo, Novartis, Pliant, ProMetic, Respivnat, Roche, Samumed and UCB.
Conflict of interest: A.A. Chetta has nothing to disclose.
Conflict of interest: P. Sestini has nothing to disclose.
Conflict of interest: A.U. Wells reports lecture fees and advisory board fees from Boeringher Ingelheim, Roche and Bayer, outside the submitted work.
Conflict of interest: E.A. Renzoni reports lecture fees and advisory board fees from Boeringher Ingelheim and Roche, and lecture fees from Mundipharma, outside the submitted work.
- Received August 28, 2019.
- Accepted October 25, 2019.
- Copyright ©ERS 2020